[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Contact ::
Main Menu
Home::
Journal Information::
Editorial Board
Aims& Scopes
Journal News
About the Journal
Articles archive::
All Issues
Current Issue
For Authors::
Call for Papers
Submission Instruction
Submission Form
Submission Checklist
For Reviewers::
Reviewers Section
Registration::
Registration Information
Registration Form
Contact us::
Contact Information
Contact us
Site Facilities::
Site map
Search contents
FAQ
Top 10 contents
Inform to friends
Medical Journalism::
Publication Ethics
::
Search in website

Advanced Search
..
INDEX









 
..
:: Volume 13, Issue 2 (12-2019) ::
Iran J Virol 2019, 13(2): 36-38 Back to browse issues page
Is SARS-CoV-2 a Product of Reverse Genetics Using Vaccinia Virus-Based Recombination?
LARS Hagen *
LARS Hagen
Abstract:   (1805 Views)
This article has no abstract.
Keywords: SARS-CoV-2, COVID-19, vaccinia virus, thymidine kinase
Full-Text [PDF 263 kb]   (2431 Downloads)    
Type of Study: Letter to editor | Subject: General
Received: 2020/04/11 | Accepted: 2019/12/16 | Published: 2019/12/16
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA

XML     Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Hagen L. Is SARS-CoV-2 a Product of Reverse Genetics Using Vaccinia Virus-Based Recombination?. Iran J Virol 2019; 13 (2) :36-38
URL: http://journal.isv.org.ir/article-1-382-en.html
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 13, Issue 2 (12-2019) Back to browse issues page
Persian site map - English site map - Created in 0.05 seconds with 38 queries by YEKTAWEB 4645